Patent ID: 11873281
Assignee: HANGZHOU DAC BIOTECH CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 7:
8. The conjugate according to claim 1, wherein the cytotoxic compound inside the bracket of Formula (I) has a structure represented by one of the following Formulae II-01˜II-69, III-01˜II-68, IV-01˜IV-68, V-01˜V-68, VI-01˜VI-12, and VII-01˜VII-77:, , , or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystalline structure thereof; or an optical isomer, racemate, diastereomer or enantiomer thereof;
wherein R20 is H; C1-C8 linear or branched alkyl, heteroalkyl, or —C(O)R17; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; —C(O)OR17, —C(O)NR17R18; or C1-C8 carboxylate, ester, ether, or amide; or 1˜8 amino acids; or polyethyleneoxy unit of formula (OCH2CH2)p or (OCH2CH(CH3))p, wherein p is an integer from 0 to about 1000; or R20 is absent and the oxygen forms a ketone, or a combination of two or more thereof, wherein R21 is H, C1-C8 linear or branched alkyl; X, X1, X2, and X3 are independently O, S, NH, NHNH, NHR17, CH2 or absent; P1 is H, R17, P(O)(OH)2, P(O)(X1R17)2, CH2P(O)(OH)2, S(O2)(X1R17), C6H12O5, or (CH2CH2O)pR17, wherein p is selected from 0-100, and R17 is defined above; in addition X1P1 can be together;
wherein Z2 and Z3 are independently H, OH, NH2, OR17, NHR17, COOH, COOR17, C(O)R17, C(O)NHR17, C(O)NHNHR17, C(O)NH2, R18, OCH2OP(O)(OR18)2, OC(O)OP(O)(OR18)2, OPO(OR18)2, NHPO(OR18)2, OP(O)(OR18)OP(O)(OR18)2, OC(O)R18, OC(O)NHR18, OSO2(OR18), O—(C4-C12-glycoside), C1-C8 linear or branched alkyl or heteroalkyl; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; —C(O)OR17, or —C(O)NR17R18; R17 and R18 are independently H, C1-C8 linear or branched alkyl or heteroalkyl; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; —C(O)OR17, or —C(O)NR17R18; R19 is H, OH, NH2, OSO2(OR18), XCH2OP(O)(OR18)2, XPO(OR18)2, XC(O)OP(O)(OR18)2, XC(O)R18, XC(O)NHR18, C1˜C8 alkyl or carboxylate; C2˜C8 alkenyl, alkynyl, alkylcycloalkyl, or heterocycloalkyl; C3˜C8 aryl or alkylcarbonyl; or a pharmaceutical salt; X is O, S, NH, NHNH, NHR7, or CH2; R7 is defined the same above;
wherein “” is the site that linked to a linker L.